Voyageurs du Monde: Growth in business activity over the full year

Growth in business activity over the full year Voyageurs du Monde Voyageurs du Monde: Growth in business activity over the full year 14-Apr-2026 / 18:34 CET/CEST Dissemination ...

Rare Earths Americas, Inc. Announces Public Filing of Registration Statement for Initial Public Offering

Rare Earths Americas, Inc. ("REA" or the "Company"), a critical minerals company advancing a portfolio of prospective heavy rare earths focused projects in the United ...

XenData, Inc.: XenData Announces Backup, Archive and Cloud-Connect for LucidLink

CAMBRIDGE, UK / ACCESS Newswire / April 14, 2026 / XenData, the provider of cutting-edge data storage solutions, announces the availability of three products that enhance LucidLink functionality: Back ...

OSE Immunotherapeutics Evolves its Leadership Team

OSE Immunotherapeutics Evolves its Leadership Team Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively Nantes, France, April 14, 2026 - 6:00pm CEST - OSE Immunotherapeutics SA ...

VINCI's Shareholders' General Meeting of 14 April 2026

Nanterre, 14 April 2026 VINCI's Shareholders' General Meeting of 14 April 2026 All resolutions passedRenewal of the terms of office of Xavier Huillard, Claude Laruelle and René Medori as DirectorsRati ...

Iconovo AB: Anders Månsson is appointed CEO

Iconovo AB (publ) has today appointed Anders Månsson as permanent CEO of Iconovo AB after approximately 6 months of service as interim CEO. Anders Månsson has worked in the company as interim CEO sinc ...

XSpray Pharma AB: FDA accepts trade name Nilopki for Xspray's drug candidate XS003 (nilotinib)

The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib ...

IMPLANET Reports Q1 2026 Revenue of €3.03 Million, up 18%

Revenue growth of +18% compared with Q1 2025 Strong momentum in the United States, +167% in Q1 2026 Business supported by the expansion of medical equipment distribution, particularly ...

Egetis Therapeutics AB: Bulletin from Egetis Therapeutics' Annual General Meeting 2026

Stockholm, Sweden, April 14, 2026. Egetis Therapeutics AB (publ) (STO: EGTX) today announced that the Annual General Meeting (AGM) has been held on April 14, 2026, at which the submitted proposals wer ...

TH International Limited: Tims China Announces Fourth Quarter and Full Year 2025 Financial Results

System Sales Increased 4.0% Year-over-Year to RMB359.4 Million 17 Net New Store Openings During the Fourth Quarter,1,047 System-Wide Stores at Year-End 2025 31.0 Million Registered Loyalty Club Member ...

Cellectar Biosciences, Inc.: Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...

CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdin ...